Bli medlem
Bli medlem

Du är här


BioStock: WntResearch reaches full operations again in NeoFox study

The NeoFox study, conducted to explore the efficacy of WntResearch's drug candidate Foxy-5, is now back in full swing. A total of 80 patients have been recruited and the company reiterates that it sees good opportunities to obtain an interim result from the study by the end of 2022. BioStock has spoken to Anders Rabbe, CEO of WntResearch, to get his view on the latest news.

Read the full article at
This is a press release from BioStock - Connecting Innovation & Capital.

Författare Cision